Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ExaWizards Inc. ( (JP:4259) ) has provided an update.
ExaWizards’ wholly owned subsidiary ExaMD Inc. has submitted a clinical trial notification to Japan’s Pharmaceuticals and Medical Devices Agency for its AI-powered cognitive function diagnostic support software, a Software as a Medical Device designated by the health ministry for priority review. The trial, targeting up to 100 participants over three months, will assess the tool’s ability to classify individuals as cognitively normal or suspected of cognitive decline using about one minute of free conversation, comparing estimated MMSE scores to measured results while monitoring safety, and the company has already factored the associated costs into its current fiscal year investment plans, indicating no change to its full-year earnings forecast at this stage.
The most recent analyst rating on (JP:4259) stock is a Hold with a Yen840.00 price target. To see the full list of analyst forecasts on ExaWizards Inc. stock, see the JP:4259 Stock Forecast page.
More about ExaWizards Inc.
ExaWizards Inc., listed on the Tokyo Stock Exchange, operates through subsidiaries such as ExaMD Inc. to develop and commercialize products and services that apply multi-modal AI technology to address social issues in healthcare, including diagnostic support solutions. ExaMD focuses on planning, development, sales, and alliances for AI-driven medical applications designed to improve clinical workflows and patient outcomes in Japan.
Average Trading Volume: 1,518,656
Technical Sentiment Signal: Buy
Current Market Cap: Yen64.06B
Find detailed analytics on 4259 stock on TipRanks’ Stock Analysis page.